Halozyme Therapeutics Inc. (HALO: Quote) announced after the close Wednesday that the Center for Biologics Evaluation and Research of the FDA has issued a complete response letter for Baxter's HyQ Biologics License Application.
Halozyme Therapeutics gapped open dramatically lower Thursday, but traded in a narrow range throughout the session. Shares finished down by 4.26 at $4.30 on the highest volume of the year. The stock plunged to a new low for the year.
Click here to receive FREE breaking news email alerts for Halozyme Therapeutics, Inc. and others in your portfolio
by RTT Staff Writer
For comments and feedback: email@example.com